STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRMD
  4. [Form 4] MARIMED INC. Insider Trading Activity

MariMed (MRMD) CFO discloses RSU conversion and tax-share withholding transactions

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc.'s Chief Financial Officer, Mario Pinho, reported equity award activity involving restricted stock units (RSUs) and common shares. On December 15, 2025, 16,075 RSUs were converted into the same number of shares of common stock at a stated price of $0, reflecting the vesting of a stock-based award.

To cover tax withholding obligations from this vesting, 4,719 shares of common stock were withheld by MariMed at a price of $0.1071 per share. After these transactions, Pinho directly owned 206,967 shares of MariMed common stock. All RSUs from the May 9, 2025 grant are now fully vested, with no unvested units remaining under that award.

Positive

  • None.

Negative

  • None.
Insider Pinho Mario
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units (RSU) 16,075 $0.00 --
Exercise Common stock 16,075 $0.00 --
Tax Withholding Common stock 4,719 $0.1071 $505.40
Holdings After Transaction: Restricted Stock Units (RSU) — 0 shares (Direct); Common stock — 211,686 shares (Direct)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. The RSUs were granted on May 9, 2025; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pinho Mario
(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY
(Street)
NORWOOD MA 02062
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 12/15/2025 M 16,075 A $0(1) 211,686 D
Common stock 12/15/2025 F 4,719(2) D $0.1071 206,967 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 12/15/2025 M 16,075 (3) (3) Common Stock, par value $.001 per share 16,075 $0 0 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. The RSUs were granted on May 9, 2025; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Mario Pinho 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MariMed (MRMD) report for its CFO?

MariMed's Chief Financial Officer, Mario Pinho, reported the vesting of 16,075 restricted stock units (RSUs) that converted into the same number of common shares on December 15, 2025.

How many MariMed (MRMD) shares were withheld for taxes in this CFO transaction?

The filing states that 4,719 shares of common stock were withheld by MariMed Inc. to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.1071 per share.

How many MariMed (MRMD) shares does the CFO own after the reported Form 4 transaction?

Following the RSU conversion and tax-share withholding, Chief Financial Officer Mario Pinho directly owns 206,967 shares of MariMed Inc. common stock.

What happened to the restricted stock units (RSUs) in MariMed (MRMD) CFO’s award?

The filing explains that 16,075 RSUs were converted into common stock on a one-for-one basis. These RSUs were granted on May 9, 2025, and there are no unvested RSUs remaining under that grant.

Was this MariMed (MRMD) CFO transaction an open-market stock sale?

The document shows RSUs converting into common shares and shares withheld by the issuer to cover tax obligations. It does not describe an open-market sale; rather, it reflects equity compensation and tax withholding mechanics.

What do the transaction codes M and F mean in the MariMed (MRMD) CFO filing?

In this report, code M corresponds to the conversion of RSUs into common shares, while code F refers to shares withheld by MariMed to pay taxes due upon the RSU vesting.